Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

This is a prospective, single-arm, multicenter, phase II clinical study designed to evaluate the initial efficacy and safety of patients receiving Tislelizumab in combination with recombinant human endostatin injection plus chemotherapy for stage III unresectable non-small cell lung cancer. To evaluate the surgical conversion rate of tirellizumab combined with recombinant human endostatin injection and chemotherapy induction therapy in patients with initially unresectable stage III non-small cell lung cancer.

Trial Details

NCT ID
NCT06617936
Phase
PHASE2
Sponsor
Hua Zhang
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • neoadjuvant therapy:Tislelizumab With Recombinant human endostatin combined with Chemotherapy
  • surgery
  • Adjuvant therapy:Tislelizumab and Recombinant Human Endostatin Injection (Endostar)
  • Standard Treatment
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Have fully understood the study and voluntarily signed the informed consent;
  • Age 18-75 years old, gender is not limited;
  • Histologically confirmed Stage III initial unresectable squamous or non-squamous non-small cell lung cancer (AJCC Stage 8th edition)
  • \- Unresectable stage III NSCLC mainly refers to imaging or lymph node pathological evidence: Multiple metastases of ipsilateral mediastinal lymph …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →